Ozempic Vs Saxenda - Guide | Cured Pharmacy

Ozempic Vs Saxenda

Saxenda

Featured Product

Saxenda

£68.00UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment →✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: 17 June 2026

Last Updated: 12 August 2026

If you have been researching weight loss injections, chances are you have come across both Ozempic and Saxenda at some point. They are two of the most talked-about injectable medications available in the UK, and while they share some similarities, they work in quite different ways and are licensed for different purposes. Understanding those differences can genuinely help you make a more informed decision about which option may be better suited to your health goals and circumstances.

Quick Summary

Both Ozempic and Saxenda belong to the GLP-1 receptor agonist class of medications and work by regulating appetite and blood sugar levels, but they contain different active ingredients and are licensed for different uses in the UK. Choosing between them depends on your individual health profile, weight loss goals, and how you prefer to administer your medication.

  • Ozempic contains semaglutide and is injected once weekly; Saxenda contains liraglutide and is injected daily
  • Ozempic is primarily licensed for type 2 diabetes management in the UK, while Saxenda is licensed specifically for weight management
  • Clinical trials suggest semaglutide produces greater average weight loss than liraglutide at therapeutic doses
  • Both carry similar gastrointestinal side effects including nausea, vomiting, and constipation
  • Neither medication is suitable as a standalone solution — both work best alongside a reduced-calorie diet and increased physical activity

Weight Loss Injection Comparison Tool

Answer a few quick questions to help identify which injection may suit your lifestyle better. This is a general guide only — always consult a prescriber before starting any medication.

1. How often are you comfortable self-injecting?

2. Do you have a diagnosis of type 2 diabetes?

3. What is your primary goal?

Table of Contents

How Ozempic and Saxenda Work in Your Body

Both Ozempic and Saxenda belong to the same family of medications known as GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, which is a naturally occurring hormone that your gut releases after eating. This hormone plays a key role in telling your brain that you are full, slowing down how quickly your stomach empties, and stimulating the pancreas to release insulin in response to rising blood sugar levels. When you take a GLP-1 medication, you are essentially amplifying these natural signals at a therapeutic level.

Saxenda contains liraglutide, which was originally developed as a diabetes treatment under the brand name Victoza before being reformulated at a higher dose for weight management. Ozempic contains semaglutide, a newer and structurally different GLP-1 agonist that was developed by the same manufacturer, Novo Nordisk. The key structural difference is that semaglutide has a longer half-life in the body, which is why Ozempic only needs to be injected once a week rather than every day. In 2026, semaglutide continues to dominate the conversation around injectable weight loss due to its potency and less frequent dosing schedule.

Both medications work on the same receptors in your brain and gut, but their molecular structures differ enough to produce meaningfully different outcomes in terms of weight loss, tolerability, and convenience. Understanding how each one interacts with your body helps explain why the clinical results between the two diverge as significantly as they do.

  • Both mimic GLP-1, a hormone that reduces appetite and slows gastric emptying
  • Liraglutide (Saxenda) has a shorter half-life and requires daily injections
  • Semaglutide (Ozempic) has a longer half-life and is injected once per week
  • Both stimulate insulin release and reduce glucagon secretion after meals
  • Neither causes weight loss on its own without lifestyle changes

Key Differences Between Ozempic vs Saxenda That Actually Matter

When people compare these two medications, the most obvious difference is the dosing frequency. Saxenda is injected subcutaneously once every day, whereas Ozempic is injected once a week. For many people, this is a significant quality-of-life consideration. Daily injections require a level of routine and commitment that not everyone finds easy to maintain, especially when travelling or during busy periods. A weekly injection offers more flexibility and may support better long-term adherence.

Beyond dosing frequency, the licensing is another critical difference that often gets overlooked. In the UK, Saxenda is specifically licensed by the MHRA for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or above, or a BMI of 27 kg/m² or above in those with at least one weight-related health condition. Ozempic, on the other hand, is licensed for the management of type 2 diabetes, not specifically for weight loss. The semaglutide product that carries a weight management licence in the UK is Wegovy, which contains a higher dose of semaglutide at 2.4 mg weekly. Ozempic comes in doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg weekly.

Cost is another practical consideration. Saxenda is generally available for weight loss treatment through private prescriptions, and pricing varies across providers. The frequency of injections with Saxenda means you will go through pens more quickly than with a weekly injection like Ozempic, which can affect the overall monthly cost of treatment.

  • Saxenda is injected daily; Ozempic is injected weekly
  • Saxenda is licensed for weight management; Ozempic is licensed for type 2 diabetes in the UK
  • Saxenda uses liraglutide at up to 3.0 mg; Ozempic uses semaglutide at up to 2.0 mg
  • Both require dose titration periods to minimise side effects
  • Ozempic may be prescribed off-label for weight loss by some clinicians

Weight Loss Results: What the Clinical Evidence Shows

The clinical evidence comparing these two medications is compelling and consistently points to semaglutide as the more potent weight loss agent. The SCALE trial programme, which evaluated liraglutide 3.0 mg (Saxenda) in adults with obesity, demonstrated an average weight reduction of around 5 to 8 percent of total body weight at 56 weeks compared to placebo. That is a meaningful result for many patients, particularly those who have struggled to lose weight through diet and exercise alone.

Semaglutide at 2.4 mg weekly, evaluated in the STEP trial programme, produced far more impressive results — an average reduction of approximately 15 percent of body weight at 68 weeks. This is more than double the average weight loss seen with liraglutide over a comparable period. A head-to-head trial published in The Lancet in 2022, known as STEP 8, directly compared once-weekly subcutaneous semaglutide 2.4 mg with daily liraglutide 3.0 mg and found that participants on semaglutide lost an average of 15.8 percent of body weight compared to 6.4 percent on liraglutide.

These results help explain why so many clinicians now default to recommending semaglutide-based treatments where accessible. That said, individual responses vary considerably, and some people do extremely well on liraglutide while experiencing poor tolerability with semaglutide. The best medication is ultimately the one that works for you as an individual, not the one that performs best on a population average.

  • Saxenda (liraglutide 3.0 mg): approximately 5–8% average weight loss at 56 weeks
  • Ozempic (semaglutide 2.4 mg in STEP trials): approximately 15% average weight loss at 68 weeks
  • STEP 8 head-to-head showed semaglutide produced more than double the weight loss of liraglutide
  • Both medications show significantly better results than placebo plus lifestyle changes
  • Long-term maintenance requires continued use; weight can return upon stopping either medication

Side Effects and Safety Considerations You Need to Know

One of the most common reasons people switch between these medications, or stop them altogether, is side effects. Because both Saxenda and Ozempic act on the same GLP-1 receptors, their side effect profiles are remarkably similar. The most frequently reported issues are gastrointestinal in nature — nausea, vomiting, diarrhoea, constipation, and stomach discomfort. These effects are typically most pronounced during dose escalation and tend to settle as your body adjusts over several weeks.

With Saxenda, the daily dosing means that nausea is experienced more frequently throughout the week in the initial stages. Some people find that this actually helps with appetite suppression, while others find it debilitating enough to discontinue treatment. With Ozempic, the once-weekly injection means that nausea tends to peak for a day or two after the injection and then subside. Some users find this pattern easier to manage, as they can plan their injection around days when nausea would be less disruptive.

Both medications carry a warning regarding a rare but serious risk of pancreatitis, and neither should be used in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Injection site reactions, including redness, bruising, or mild swelling, are also common with both. It is essential to rotate injection sites to minimise this. If you are exploring medical weight loss options, always ensure you are assessed by a qualified UK prescriber before starting either treatment.

  • Nausea is the most commonly reported side effect with both medications
  • Gastrointestinal side effects are usually worst during dose escalation
  • Both carry a rare risk of pancreatitis — seek urgent care if you develop severe abdominal pain
  • Neither is suitable for use in pregnancy or breastfeeding
  • Both can slow gastric emptying, which may affect the absorption of oral medications taken at the same time

Who Is Suitable for Each Medication?

Saxenda is licensed in the UK as a weight management aid for adults with a BMI of 30 or above, or 27 or above if they have a weight-related condition such as high blood pressure, pre-diabetes, or obstructive sleep apnoea. It is suitable for use alongside a calorie-reduced diet and increased physical activity. It is not recommended for people with a history of pancreatitis, severe renal impairment, or inflammatory bowel disease.

Ozempic is primarily prescribed in the UK for people with type 2 diabetes, either as an add-on to other diabetes medications or as monotherapy when other options are not appropriate. However, because of the clinical evidence showing its significant impact on weight, some clinicians do prescribe it off-label for weight management in patients who do not have diabetes. This practice is not universally endorsed, and the MHRA-approved weight loss indication for semaglutide in the UK sits with Wegovy, not Ozempic.

Both medications are contraindicated in pregnancy, and women of childbearing age should use effective contraception during treatment. People with a history of eating disorders, severe depression, or suicidal ideation should be carefully assessed before starting either treatment, as weight loss interventions can sometimes interact with mental health conditions in complex ways. Your prescriber will conduct a thorough review of your medical history to determine whether either medication is appropriate for you.

  • Saxenda is suitable for BMI over 30, or over 27 with a weight-related health condition
  • Ozempic is primarily for type 2 diabetes but may be considered off-label for weight loss
  • Neither is suitable during pregnancy, breastfeeding, or in people with medullary thyroid cancer history
  • Both require a clinical assessment and valid prescription from a registered UK prescriber
  • Regular monitoring and follow-up appointments are recommended with either treatment

Full Side-by-Side Comparison Table

Feature Saxenda (Liraglutide) Ozempic (Semaglutide)
Active ingredient Liraglutide Semaglutide
Injection frequency Once daily Once weekly
UK licence Weight management (BMI ≥30 or ≥27 with comorbidity) Type 2 diabetes management
Maximum dose 3.0 mg daily 2.0 mg weekly (up to 2.4 mg in Wegovy)
Average weight loss 5–8% body weight at 56 weeks ~15% body weight at 68 weeks (STEP trials)
Dose titration period 5 weeks to reach full dose 16–20 weeks to reach full dose
Common side effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation
Suitable for type 2 diabetes Not specifically licensed for diabetes Yes, primary indication
Manufacturer Novo Nordisk Novo Nordisk
Available on NHS Limited; primarily private prescription Yes, for eligible type 2 diabetes patients
Pen device Pre-filled injection pen Pre-filled injection pen
Storage Refrigerate before first use; room temperature after opening Refrigerate before first use; room temperature after opening

Key Takeaways

  • Ozempic and Saxenda both work as GLP-1 receptor agonists but contain different active ingredients — semaglutide and liraglutide respectively — and are licensed for different indications in the UK
  • Saxenda is the only one of the two that carries a direct UK licence for weight management, making it the more straightforward choice when weight loss is your primary goal
  • Clinical evidence consistently shows that semaglutide produces greater average weight loss than liraglutide, with the STEP 8 trial demonstrating more than double the weight reduction
  • Both medications share a similar gastrointestinal side effect profile, with nausea being the most commonly reported issue, especially during dose escalation
  • The right choice between the two depends on your individual health profile, lifestyle, and goals — always seek advice from a qualified UK prescriber before starting either medication

When to Seek Professional Advice

You should speak to a qualified prescriber before starting either Saxenda or Ozempic, full stop. These are prescription-only medications and must not be obtained or used without a proper medical consultation. A prescriber will review your BMI, existing health conditions, current medications, and personal goals to determine whether either medication is appropriate and safe for you.

If you are already on one of these medications and you experience severe or persistent nausea and vomiting, sudden and severe abdominal pain, changes in heart rate, signs of an allergic reaction (such as swelling of the face or throat), or unexplained changes in your mood or mental health, stop using the medication and seek medical attention promptly. These may indicate a serious adverse reaction that requires clinical assessment.

You should also seek advice if you are not seeing any meaningful results after 12 to 16 weeks of treatment at the recommended dose, as this may indicate that an alternative approach or a different medication would be more effective for you. Cured Pharmacy offers access to clinically approved weight loss treatments with a straightforward online consultation process reviewed by UK-based prescribers, so you can get professional guidance from the comfort of your own home.

Scientific References

  1. Wadden TA, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." STEP 8: The Lancet, 2022. [Accessed 12 August 2026]
  2. NICE Technology Appraisal TA664: Liraglutide (Saxenda) for Managing Overweight and Obesity. National Institute for Health and Care Excellence, 2020. [Accessed 12 August 2026]
  3. Saxenda 6 mg/mL solution for injection — Summary of Product Characteristics. Electronic Medicines Compendium (eMC), Novo Nordisk. [Accessed 12 August 2026]
  4. NICE Technology Appraisal TA664: Semaglutide for managing overweight and obesity, NICE, 2023 [Accessed 12 August 2026]
  5. NICE Technology Appraisal TA875: Liraglutide for managing overweight and obesity, NICE, 2023 [Accessed 12 August 2026]
  6. Ozempic 0.5mg, 1mg and 2mg solution for injection – Summary of Product Characteristics, Electronic Medicines Compendium (EMC), Novo Nordisk, 2023 [Accessed 12 August 2026]
  7. Saxenda 6mg/mL solution for injection – Summary of Product Characteristics, Electronic Medicines Compendium (EMC), Novo Nordisk, 2023 [Accessed 12 August 2026]
  8. Diabetes UK Position Statement: Treatment of Obesity in Adults with Type 2 Diabetes, Diabetes UK, 2021 [Accessed 12 August 2026]
  9. Davies M et al., Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, placebo-controlled, phase 3 trial, Diabetes, Obesity and Metabolism, 2021 [Accessed 12 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Frequently Asked Questions

How long does it take to see weight loss results with Saxenda or Ozempic?

How long it takes to see weight loss results with Saxenda or Ozempic varies by person, but most people notice changes within 4 to 8 weeks. Saxenda reaches its full therapeutic dose over five weeks, while Ozempic is titrated over several months. Significant results are typically seen after 12 to 16 weeks of consistent use.

Is it safe to switch from Saxenda to Ozempic?

Switching from Saxenda to Ozempic is generally considered safe under medical supervision, but it is not something you should do without consulting a prescriber first. Both are GLP-1 receptor agonists, so a washout period may not always be required, but your dose titration schedule and suitability must be reassessed individually.

Can you take Saxenda or Ozempic if you have type 2 diabetes?

You can take Saxenda or Ozempic if you have type 2 diabetes, though Ozempic is specifically licensed for blood sugar management in type 2 diabetes in the UK. Saxenda is licensed only for weight management. Your prescriber will assess your full medical history before recommending the most appropriate treatment for your needs.

What is the maximum dose of Saxenda and how does it compare to Ozempic?

The maximum dose of Saxenda is 3.0 mg injected daily, reached gradually over five weeks. Ozempic reaches a maximum dose of 2.0 mg injected once weekly. Saxenda uses liraglutide while Ozempic uses semaglutide, a more potent GLP-1 agonist, which is why Ozempic generally produces greater weight loss at lower doses.

Back to blog